As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't

A close­ly watched “break­through” asth­ma drug has hit all the right notes in a Phase III, As­traZeneca and Am­gen say, paving the way to reach a cur­rent­ly un­tapped pa­tient pop­u­la­tion.

We’re not get­ting much be­yond the an­nounce­ment that teze­pelum­ab met the pri­ma­ry end­point, but ex­ecs’ en­thu­si­as­tic com­ments sug­gest that what they’re see­ing backs up the “un­prece­dent­ed” re­sults that ce­ment­ed their FDA break­through des­ig­na­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.